Bone News and Research

RSS

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

Two teams led by Massachusetts General Hospital (MGH) researchers, also members of the Harvard Stem Cell Institute (HSCI), are among 18 groups receiving National Heart Lung and Blood Institute (NHLBI) grants for the development of stem-cell based tools and treatments to understand and treat cardiovascular and blood disorders.

9 Oct 2009

Gluten-free diet leads to complete recovery of bone mineralization in CD affected children

Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.

9 Oct 2009

Kaiser Permanente launches osteoporosis prevention campaign

Encouraging everyone to “Embrace Your Inner Strength,” Kaiser Permanente has launched a campaign throughout Southern California aimed at getting teenagers, seniors and everyone in between to get serious about building up their skeletons and preventing osteoporosis.

8 Oct 2009

New mechanism of bone formation may help fight osteoporosis

The natural cycle of building bone to maintain skeletal strength and then breaking it down for the body's calcium needs is delicately balanced, but diseases like osteoporosis break down too much bone without adequate bone replacement, leading to bone fractures.

8 Oct 2009

CTRC-AACR San Antonio Breast Cancer Symposium to honor two leading breast cancer researchers

The CTRC-AACR San Antonio Breast Cancer Symposium will honor two leading breast cancer researchers when it holds its 32nd annual meeting Dec. 9-13, in San Antonio.

8 Oct 2009

Coeliac disease patients at risk of osteoporosis

People with coeliac disease may develop osteoporosis because their immune system attacks their bone tissue, a new study has shown.

8 Oct 2009

Misonix signs exclusive distribution agreement with Neurotechnics

Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Neurotechnics Ltd., based in Banbury, England, for the distribution of the BoneScalpel(TM) Ultrasonic Bone Cutter.

8 Oct 2009

New England Donor Registry launched by Donate Life

Donate Life New England, a joint project of two federally designated organ procurement organizations that serve New England, today announced that individuals can now – for the first time – enroll online in the New England Donor Registry at www.donatelifenewengland.org.

8 Oct 2009

New apoptosis detection kit for monitoring chromatin condensation

Enzo Biochem, Inc.’s Enzo Life Sciences division today announced the addition of a new apoptosis detection kit for monitoring chromatin condensation to its rapidly expanding CELLestial™ product line for live cell analysis.

7 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis

Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.

7 Oct 2009

Minimally invasive sling operations for stress urinary incontinence found promising

New, less invasive surgical treatments for stress urinary incontinence in women are just as effective as traditional open surgical approaches, according to Cochrane Researchers. The researchers carried out a systematic review of trials comparing different surgical approaches to treating the condition.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

Patients and surgeons drive demand for elective orthopedic procedures despite economic slowdown

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, patients and surgeons are driving demand for elective orthopedic procedures.

7 Oct 2009

CML Healthcare Income Fund to acquire two medical imaging operations

CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today announced that its operating subsidiary, CML HealthCare Inc. ("CML") has entered into definitive agreements to acquire two medical imaging operations comprising six centers located in the Northeast United States.

7 Oct 2009

Galapagos receives EUR 500,000 cash payment from GSK

Galapagos NV (Euronext: GLPG) announced today that it has reached the first milestone in its antibacterials and antivirals alliance with GlaxoSmithKline (GSK). For achieving this milestone, Galapagos receives a EUR 500,000 cash payment from GSK.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

NIDCR announces research and technology grants to support new Facebase Consortium

The integration process just got a lot easier. The National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health, announced today it has issued the first 11 research and technology grants of its new FaceBase Consortium.

7 Oct 2009